Wu Ying, Qi Han, Cao Fei, Shen Lujun, Chen Shuanggang, Xie Lin, Huang Tao, Song Ze, Zhou Danyang, Fan Weijun
Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Pharmacol. 2020 Jul 29;11:1130. doi: 10.3389/fphar.2020.01130. eCollection 2020.
To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC).
This retrospective study examined 50 patients with huge unresectable HCC treated from January 2009 to December 2015. Among them, 28 cases received TACE-sorafenib treatment (TACE-sorafenib group), and 22 cases received TACE-sorafenib plus thermal ablation treatment (TACE-sorafenib-thermal ablation group). The Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared.
The median follow-up was 13.5 months (ranges 4.2 to 96.7 months). The median OS was significantly longer in the TACE-sorafenib-thermal ablation group than that in the TACE-sorafenib group (20.8 vs. 10.4 months, =0.003). The median PFS of the ablation and no ablation groups were 4.3 vs. 7.1 months (=0.546). The treatment modality was an independent predictor of OS (=0.004). There were no notable drug-related high grade adverse events or permanent adverse sequelae.
TACE-sorafenib-thermal ablation provided extended OS to patients with huge unresectable HCC and could be a better choice than TACE-sorafenib.
探讨经动脉化疗栓塞术（TACE）联合索拉非尼及热消融治疗巨大肝细胞癌（HCC）患者的有效性和安全性。
本回顾性研究纳入了2009年1月至2015年12月期间接受治疗的50例无法切除的巨大HCC患者。其中，28例接受TACE-索拉非尼治疗（TACE-索拉非尼组），22例接受TACE-索拉非尼加热消融治疗（TACE-索拉非尼-热消融组）。比较总生存期（OS）、无进展生存期（PFS）和不良事件（AE）。
中位随访时间为13.5个月（范围4.2至96.7个月）。TACE-索拉非尼-热消融组的中位OS显著长于TACE-索拉非尼组（20.8对10.4个月，P = 0.003）。消融组和未消融组的中位PFS分别为4.3和7.1个月（P = 0.546）。治疗方式是OS的独立预测因素（P = 0.004）。未出现明显的药物相关高级别不良事件或永久性不良后遗症。
TACE-索拉非尼-热消融术可延长无法切除的巨大HCC患者的OS，可能是比TACE-索拉非尼更好的选择。
Zotero 插件
